Drug intelligence / Profile preview

Maxol

Development stage: Unknown
Lead developer: Maxitech Pharma
Modality: Small Molecules
Administration: Oral

Overview

Maxol is an oral generic formulation of esomeprazole developed and marketed by Maxitech Pharma. As a proton pump inhibitor (PPI), esomeprazole works by covalently and irreversibly inhibiting the gastric H+/K+-ATPase (proton pump) in the parietal cells of the stomach lining, thereby blocking the final step of gastric acid secretion. Maxol is approved and marketed as 20 mg and 40 mg capsules for the treatment of acid-related gastrointestinal disorders, including gastroesophageal reflux disease (GERD), peptic ulcer disease, and Zollinger-Ellison syndrome.

Brand names: Maxol
Other names: esomeprazole

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on Maxol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Maxol.

Explore the full profile